Safe & Green Holdings Reports Second Quarter 2024 Results and Provides a Business Update
Gross profit increases over four-fold; operating expenses reduced 48% Reports record sales pipeline in excess of $25 million On track […]
XWELL, Inc. Reports Second Quarter 2024 Results
NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness […]
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of […]
BIO-key Reports Reduced Net Loss and Cash Used in Operations on Lower Q2’24 Revenues; Hosts Investor Call Thu. Aug. 15th at 10am ET
HOLMDEL, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) — BIO-key®International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity […]
POET Technologies Reports Second Quarter 2024 Financial Results
TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the […]
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company […]
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical […]
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of […]
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action […]
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Presented Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186Re) Obisbemeda for Leptomeningeal MetastasesPresented Positive Topline Clinical Trial Results for […]
